FDA grants Arrowhead's plozasiran entry into STAR pilot program

Go back to FDA grants Arrowhead's plozasiran entry into STAR pilot program

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

October 7, 2026 7:30 AM EDT

- FDA STAR pilot program aims to shorten the time from complete supplement submission to the action date to allow earlier patient access to therapies that address an unmet medical need

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug... More